Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: preliminary clinical experience.

Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: preliminary clinical experience. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: preliminary clinical experience. Abstract Text:

Y Korogi,T Hirai,R Nishimura,S Hamatake,Y Sakamoto,R Murakami,Y Baba,A Arakawa,M Takahashi,Y Uji,

OBJECTIVE. The purpose of this study was to assess the initial clinical response to superselective intraarterial infusion of cisplatin for treating stage III and stage IV squamous cell carcinoma of the mouth. SUBJECTS AND METHODS. Thirteen patients received intraarterial cisplatin therapy. The tumors were located in the tongue (n = 7), gingiva (n = 3), buccal mucosa (n = 1), hard palate (n = 1), and floor of the mouth (n = 1). A coaxial technique was used to place microcatheters in the lingual, facial, inferior alveolar, buccinator, and distal internal maxillary arteries, depending on tumor location. The feeding vessels were identified by staining the tumor with infusion of indigocarmine dye in the selected vessel. Relatively low-dose cisplatin (30-40 mg/m2) was injected at the rate of 50 mg/hr. Two or three injections were performed, with a 1-week interval between injections. After chemotherapy, eight patients underwent surgery, four had radiation therapy, and one had both. RESULTS. Thirty-four intraarterial infusions were done successfully without any complications. Arterial infusion of indigocarmine dye was useful for exact identification of feeding vessels, especially when the tumor was extensive, at the margin of the arterial supply, or near the midline. The overall response rate was 92% (complete response [tumor completely resolved], 38%; partial response [tumor reduction > or = 50%], 54%). Ten of 13 patients had no recurrence from 4 to 19 months (mean, 10 months) after treatment. Two patients died of metastatic diseases 6 months after surgery or radiation therapy. One patient had local recurrence 8 months after surgery and postoperative irradiation. No systemic toxicity such as renal failure, liver dysfunction, or bone marrow suppression was observed. Mild and transient local toxicity such as edema or mucositis of the infused area was relatively common. Trigeminal neuralgialike symptoms and reduced mouth opening occurred in two cases and one case, respectively, probably due to direct toxicity to the peripheral trigeminal nerve and masticatory muscles, respectively. CONCLUSION. Superselective intraarterial infusion of low-dose cisplatin is feasible and safe and may have important applications in treating advanced carcinoma of the mouth.

Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: preliminary clinical experience. Publishing Authors By Initials

Y Korogi,T Hirai,R Nishimura,S Hamatake,Y Sakamoto,R Murakami,Y Baba,A Arakawa,M Takahashi,Y Uji,

For similar health occupations: medicine: specialties, medical: radiology: radiology, interventional research abstracts see: health occupations: medicine: specialties, medical: radiology: radiology, interventional research

PUBMED ID PMID:

MEDLINE DATE:

Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: preliminary clinical experience. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: AJR. American journal of roentgenology

VOLUME: 165

Page Numbers: 1269-72

Journal Abbreviation:

ISSN: 0361-803X

DAY: 15

MONTH: Nov

YEAR: 1995

Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: preliminary clinical experience. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7708173

Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: preliminary clinical experience. Keywords Mesh Terms:

KEYWORDS: Radiology, Interventional

MESH TERMS: radiography

Chemical & Substance for Abstract: Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: preliminary clinical experience. Information

Substance Name: Indigotindisulfonate Sodium

Registry Number: 860-22-0

Grant and Affiliation Information for Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: preliminary clinical experience.

AFFILIATION: Department of Radiology, Kumamoto University School of Medicine, Japan.

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: AJR Am J Roentgenol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: preliminary clinical experience Related Publications

• Characterization and tissue distribution of multiple agouti-family genes in pufferfish, Takifugu rubripes.
• Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
• Fermi Surface Properties of CeRu2(Si1-xGex)_{2} in Magnetic Fields above the Metamagnetic Transitions.
• Genomic characterization and tissue distribution of leptin receptor and leptin receptor overlapping transcript genes in the pufferfish, Takifugu rubripes.
• Inducible nitric oxide synthase mediates retinal DNA damage in Goto-Kakizaki rat retina.
• Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: preliminary clinical experience.
• The use of colour Doppler imaging in the diagnosis of retinal detachment.
• Ultrasound biomicroscopy for membranous congenital cataract.
• Vogt-Koyanagi-Harada syndrome in a pregnant patient treated with high-dose systemic corticosteroids.